A detailed history of Oakworth Capital, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Oakworth Capital, Inc. holds 10,984 shares of ABBV stock, worth $1.98 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
10,984
Previous 13,756 20.15%
Holding current value
$1.98 Million
Previous $2.36 Million 8.05%
% of portfolio
0.15%
Previous 0.17%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$163.84 - $199.33 $454,164 - $552,542
-2,772 Reduced 20.15%
10,984 $2.17 Million
Q2 2024

Jul 19, 2024

SELL
$154.79 - $180.76 $28,326 - $33,079
-183 Reduced 1.31%
13,756 $2.36 Million
Q1 2024

Apr 22, 2024

BUY
$159.82 - $182.1 $114,590 - $130,565
717 Added 5.42%
13,939 $2.54 Million
Q4 2023

Jan 30, 2024

BUY
$137.6 - $154.97 $12,384 - $13,947
90 Added 0.69%
13,222 $2.05 Million
Q3 2023

Oct 31, 2023

SELL
$133.59 - $154.65 $8,282 - $9,588
-62 Reduced 0.47%
13,132 $1.96 Million
Q2 2023

Jul 28, 2023

BUY
$132.51 - $164.9 $4,372 - $5,441
33 Added 0.25%
13,194 $1.78 Million
Q1 2023

May 02, 2023

BUY
$144.61 - $166.54 $94,141 - $108,417
651 Added 5.2%
13,161 $2.1 Million
Q4 2022

Feb 03, 2023

SELL
$138.31 - $165.87 $69,155 - $82,935
-500 Reduced 3.84%
12,510 $2.02 Million
Q3 2022

Oct 31, 2022

SELL
$134.21 - $153.93 $1,342 - $1,539
-10 Reduced 0.08%
13,010 $1.75 Million
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $6,192 - $7,873
-45 Reduced 0.34%
13,020 $1.99 Million
Q1 2022

Apr 11, 2022

BUY
$131.98 - $163.75 $97,797 - $121,338
741 Added 6.01%
13,065 $2.12 Million
Q4 2021

Feb 07, 2022

BUY
$107.43 - $135.93 $61,235 - $77,480
570 Added 4.85%
12,324 $1.67 Million
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $30,856 - $35,026
290 Added 2.53%
11,754 $1.27 Million
Q2 2021

Jul 20, 2021

BUY
$105.21 - $117.21 $25,039 - $27,895
238 Added 2.12%
11,464 $1.29 Million
Q1 2021

Apr 30, 2021

BUY
$102.3 - $112.62 $124,601 - $137,171
1,218 Added 12.17%
11,226 $1.22 Million
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $17,385 - $23,472
216 Added 2.21%
10,008 $1.07 Million
Q3 2020

Nov 09, 2020

SELL
$85.91 - $100.83 $4,467 - $5,243
-52 Reduced 0.53%
9,792 $858,000
Q2 2020

Aug 11, 2020

SELL
$73.37 - $98.18 $660 - $883
-9 Reduced 0.09%
9,844 $967,000
Q1 2020

May 07, 2020

BUY
$64.5 - $97.79 $111,391 - $168,883
1,727 Added 21.25%
9,853 $750,000
Q4 2019

Jan 31, 2020

BUY
$72.13 - $90.25 $49,769 - $62,272
690 Added 9.28%
8,126 $727,000
Q3 2019

Nov 13, 2019

SELL
$62.98 - $75.72 $25,380 - $30,515
-403 Reduced 5.14%
7,436 $563,000
Q2 2019

Aug 02, 2019

SELL
$65.7 - $83.98 $33,572 - $42,913
-511 Reduced 6.12%
7,839 $570,000
Q1 2019

May 06, 2019

SELL
$77.14 - $90.79 $67,806 - $79,804
-879 Reduced 9.52%
8,350 $673,000
Q4 2018

Feb 13, 2019

SELL
$77.85 - $96.01 $1,557 - $1,920
-20 Reduced 0.22%
9,229 $851,000
Q3 2018

Oct 25, 2018

SELL
$88.91 - $98.84 $1,066 - $1,186
-12 Reduced 0.13%
9,249 $875,000
Q1 2018

May 09, 2018

BUY
$92.01 - $123.21 $2,760 - $3,696
30 Added 0.32%
9,261 $894,000
Q4 2017

Jan 22, 2018

SELL
$89.56 - $98.21 $227,482 - $249,453
-2,540 Reduced 21.58%
9,231 $894,000
Q3 2017

Nov 08, 2017

BUY
$69.85 - $89.22 $822,204 - $1.05 Million
11,771
11,771 $886,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Oakworth Capital, Inc. Portfolio

Follow Oakworth Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oakworth Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oakworth Capital, Inc. with notifications on news.